Clinicians should no longer prescribe ketoconazole (Nizoral, Janssen Pharmaceuticals) tablets as a first-line therapy for any fungal infection because of the risk for severe liver injury, adrenal ...

The US Food and Drug Administration (FDA) is warning clinicians against the off-label prescribing of ketoconazole tablets (Nizoral, Janssen Pharmaceuticals) to treat skin and nail fungal infections ...

The labeling for the antifungal product Nizoral (ketoconazole; Janssen) tablets has been updated to include warnings indicating that the drug can cause severe liver injuries and adrenal gland problems ...

Please provide your email address to receive an email when new articles are posted on . Ketoconazole oral tablets should no longer be a first-line treatment for fungal infections, according to a ...

WASHINGTON (AP) — A consumer safety group is calling on the Food and Drug Administration to pull certain antifungal tablets off the market, saying there are safer medicines that do not carry risks of ...

Please provide your email address to receive an email when new articles are posted on . Results from a small survey suggest that endocrinologists were unaware of the safety risks, including adrenal ...

HealthDay News — The FDA has approved several labeling changes for oral ketoconazole (Nizoral) tablets to limit it’s use after concerns the medication can cause severe liver injuries and adrenal gland ...

Ketoconazole is a well-known CYP17-targeted systemic treatment for castration-resistant prostate cancer (CRPC). However, most of the published data has been in the pre-chemotherapy setting; its ...